A 57-year-old woman with ES-SCLC was administered a combination therapy of atezolizumab (a PD-L1 inhibitor) and anlotinib [an oral multi-targeted tyrosine kinase inhibitor (TKI)]. She survived for 22 months, with no disease progression during the 28 courses of therapy. Unexpectedly, despite having no history of asthma, the patient developed asthma while receiving this regimen. This is possibly related to T-cell activation and the tumor immune microenvironment, which induce allergic inflammation after PD-L1 blockade.
This is the first report of an asthma-negative ES-SCLC patient who developed asthma after receiving atezolizumab plus anlotinib. Although this combination therapy may effectively extend survival in SCLC patients, asthmatic symptoms should be closely monitored.
■一名患有ES-SCLC的57岁女性患者接受了阿特珠单抗(PD-L1抑制剂)和安洛替尼[一种口服多靶向酪氨酸激酶抑制剂(TKI)]的联合治疗。她活了22个月,在28个疗程的治疗过程中没有疾病进展。出乎意料的是,尽管没有哮喘病史,患者在接受该方案时出现哮喘.这可能与T细胞活化和肿瘤免疫微环境有关,在PD-L1阻断后诱导过敏性炎症。
■这是首例哮喘阴性ES-SCLC患者在接受阿特珠单抗联合安洛替尼后发展为哮喘的报告。虽然这种联合治疗可以有效延长SCLC患者的生存期,应密切监测哮喘症状。